Analysis Indicates that Patients Requiring Blood Transfusions and Receiving Endari Required ~43% Fewer Units of Red Blood Cells
Read More
Emmaus invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com
Read More
Emmaus Life Sciences, Inc. today announced that data on Endari® has been accepted for a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition.
Read More
Emmaus Life Sciences, Inc. today reported financial results for the quarter and nine months ended September 30, 2021.
Read More
Emmaus Life Sciences, Inc. today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.
Read More